H00005 | |
H number | H00005 |
Name | Chronic lymphocytic leukemia |
Description | Chronic lymphocytic leukemia (CLL) is caused by the abnormal progressive accumulation of functionally incompetent monoclonal B-lymphocytes in blood, bone marrow, lymph nodes and spleen. It is the most common adult leukemia in Western countries, accounting for about 30% of total leukaemias. Worldwide there are approximately 180,000 new cases every year. A main focus in CLL research involved the evaluation of genetic features related to somatic gene mutation or deletions that disrupt apoptosis and enhance tumor cell proliferation. The best characterized genes are TP53 (also known as p53) and ATM, for which mutations and/or deletions have been described that predict rapid disease progression, resistance to conventional therapies and poor survival. |
Category | Cancer |
Network | - |
Gene | Bcl-2 (overexpression) [HSA:596] [KO:K02161] p53 (mutation) [HSA:7157] [KO:K04451] ATM (germline and somatic mutation) [HSA:472] [KO:K04728] Fas (absent) [HSA:355] [KO:K04390] |
Pathogen | - |
Env factor | - |
Carcinogen | - |
Drug | Cyclophosphamide [DR:D00287] Chlorambucil [DR:D00266] Bendamustine hydrochloride [DR:D07085] Fludarabine phosphate [DR:D01907] Ibrutinib [DR:D10223] (chromosome 17p deletion) Acalabrutinib [DR:D10893] Idelalisib [DR:D10560] Duvelisib hydrate [DR:D11658] Rituximab [DR:D02994] (CD20-positive) Rituximab and hyaluronidase [DR:D11393] Ofatumumab [DR:D09314] Obinutuzumab [DR:D09321] Venetoclax [DR:D10679] (chromosome 17p deletion) Alemtuzumab [DR:D02802] Sodium phosphate P 32 [DR:D05870] Ibritumomab tiuxetan [DR:D04489] (CD20-directed) |
Comment | - |
Other DBs | ICD-11: 2A82.0 ICD-10: C91.1 MeSH: D015451 |
Reference | PMID:18059180 AUTHORS Chen J, McMillan NA TITLE Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia. JOURNAL Cancer Biol Ther 7:174-9 (2008) DOI:10.4161/cbt.7.2.5262 PMID:17961188 AUTHORS Plass C, Byrd JC, Raval A, Tanner SM, de la Chapelle A TITLE Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes. JOURNAL Br J Haematol 139:744-52 (2007) DOI:10.1111/j.1365-2141.2007.06875.x PMID:10687725 AUTHORS Bannerji R, Byrd JC. TITLE Update on the biology of chronic lymphocytic leukemia. JOURNAL Curr Opin Oncol 12:22-9 (2000) DOI:10.1097/00001622-200001000-00004 PMID:11491097 AUTHORS Caligaris-Cappio F. TITLE Biology of chronic lymphocytic leukemia. JOURNAL Rev Clin Exp Hematol 4:5-21 (2000) DOI:10.1046/j.1468-0734.2000.00001.x PMID:9498905 AUTHORS Blair A, Kazerouni N. TITLE Reactive chemicals and cancer. JOURNAL Cancer Causes Control 8:473-90 (1997) DOI:10.1023/a:1018417623867 PMID:16155477 AUTHORS Graff JJ, Sathiakumar N, Macaluso M, Maldonado G, Matthews R, Delzell E. TITLE Chemical exposures in the synthetic rubber industry and lymphohematopoietic cancer mortality. JOURNAL J Occup Environ Med 47:916-32 (2005) DOI:10.1097/01.jom.0000172866.16615.db PMID:15660110 AUTHORS Luch A. TITLE Nature and nurture - lessons from chemical carcinogenesis. JOURNAL Nat Rev Cancer 5:113-25 (2005) DOI:10.1038/nrc1546 PMID:12464351 AUTHORS Kolman A, Chovanec M, Osterman-Golkar S. TITLE Genotoxic effects of ethylene oxide, propylene oxide and epichlorohydrin in humans: update review (1990-2001). JOURNAL Mutat Res 512:173-94 (2002) DOI:10.1016/S1383-5742(02)00067-4 PMID:16873420 AUTHORS Alder N, Fenty J, Warren F, Sutton AJ, Rushton L, Jones DR, Abrams KR. TITLE Meta-analysis of mortality and cancer incidence among workers in the synthetic rubber-producing industry. JOURNAL Am J Epidemiol 164:405-20 (2006) DOI:10.1093/aje/kwj252 PMID:16299089 AUTHORS Sathiakumar N, Graff J, Macaluso M, Maldonado G, Matthews R, Delzell E. TITLE An updated study of mortality among North American synthetic rubber industry workers. JOURNAL Occup Environ Med 62:822-9 (2005) DOI:10.1136/oem.2004.018176 |